Why in News?
On May 14, 2026, India's Technology Development Board (TDB) partnered with Helix Cell Therapeutics to fund and launch Phase I trials for a next-generation dual-targeting CAR-T cell therapy.
About
- Cellular Malignancy: Occurs when white blood cells called plasma cells (which normally produce infection-fighting antibodies) clone themselves uncontrollably.
- Monoclonal Proteins (M-Spike): The cancerous plasma cells produce a single, defective type of antibody—known as a monoclonal protein or M-protein—which crowds out healthy blood cells.
- The "CRAB" Complications: The proliferation of abnormal cells triggers four definitive physiological damages:
- Calcium Elevation (hypercalcemia from bone destruction).
- Renal Damage (kidney failure due to toxic protein buildup).
- Anemia (severe fatigue caused by depleted red blood cell counts).
- Bone Disease (osteolytic lesions, thinning, and frequent fractures).
- Demographics: Typically diagnosed in individuals aged 60 to 70, though it is increasingly being detected in younger populations between 40 and 60.
Evolution of Treatment & 2026 Frameworks
- The "Off-The-Shelf" Shift: Bispecific antibodies (like Teclistamab and Linvoseltamab) are now standard at the very first relapse. They engineer the body's native T-cells to attack the cancer without requiring complex, multi-week cell harvesting.
- Quadruplet Therapies: In January 2026, the FDA approved the D-VRd quadruplet regimen (Daratumumab + Bortezomib + Lenalidomide + Dexamethasone) for newly diagnosed patients ineligible for stem cell transplants, significantly improving remission longevity.
- Dual-Targeting CAR-T: Moving beyond single-target (BCMA) variations, new 2026 trials utilize dual-targeting (BCMA + CD19) to prevent cancer cells from adapting, mutating, or evading standard immunotherapies.
- MRD-Adaptive Strategies: Oncologists now rely heavily on Minimal Residual Disease (MRD) testing—the deepest diagnostic tool available—to measure trace cancer cells and tailor ongoing maintenance therapies.
Download Pdf
